Just in case you thought your doctor was your friend, remember that you are a customer and your disease is to be “managed”, not cured, for a cure curtails profits.
The American Medical Association (AMA) trademarked the word “cure” so healers can’t use it, which is just as well, because healing is something altogether different than managing symptoms of disease with toxic chemicals, or cutting the body open with sharp knives to correct a perceived condition, which very well may return because the root cause has not been addressed.
Thank God for emergency room MDs who set broken bones and patch up wounds from accidents. We sometimes need their services. They are in a different world from other doctors. They are a step above. They truly serve.
Med school students go through hell to graduate. They usually leave school saddled with huge debt. They need to make their specialty pay. They often have to compromise their original, sincere desire to help people get well, so they can pay their office rent and salaries. Is it any wonder doctors commit suicide more often than any other profession?
Compassion for people in the medical field is a beautiful thing. But always get a second opinion.
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.
“Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.”
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow”…